View Financial HealthCellSeed 배당 및 자사주 매입배당 기준 점검 0/6CellSeed 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 24CellSeed Inc. to Report Q1, 2026 Results on May 13, 2026CellSeed Inc. announced that they will report Q1, 2026 results on May 13, 2026공시 • Feb 16CellSeed Inc., Annual General Meeting, Mar 25, 2026CellSeed Inc., Annual General Meeting, Mar 25, 2026.공시 • Dec 03CellSeed Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026CellSeed Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026공시 • Nov 20CellSeed Inc. announced that it expects to receive ¥3.44 million in funding from Barclays Bank PLC, Investment ArmCellSeed Inc. announced a private placement by the Resolution of the Board of Directors to issue 86,000 25th Series of Stock Acquisition Rights at a price of ¥40 per stock acquisition right for gross proceeds of ¥3,440,000 on November 20, 2025. The transaction includes participation from Barclays Bank PLC. The Stock Acquisition Rights are convertible into 8,600,000 Ordinary Shares for gross proceeds of ¥3,268,000,000. The initial exercise price will be ¥380. On or after December 9, 2025, the exercise price will be revised on the effective date of each exercise request for the Stock Acquisition Rights to an amount equivalent to 97% of the closing price of the Company's common shares in regular trading on the Tokyo Stock Exchange on the trading day immediately preceding the revision date. If the revised exercise price based on this calculation falls below the minimum exercise price, the minimum exercise price will be the revised exercise price. The exercise period starts from from December 9, 2025 to December 8, 2027.New Risk • Oct 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).New Risk • Oct 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.5b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Market cap is less than US$100m (JP¥14.5b market cap, or US$99.1m).공시 • Sep 27CellSeed Inc. to Report Q3, 2025 Results on Nov 13, 2025CellSeed Inc. announced that they will report Q3, 2025 results on Nov 13, 2025공시 • Jun 17CellSeed Inc. to Report Q2, 2025 Results on Aug 13, 2025CellSeed Inc. announced that they will report Q2, 2025 results on Aug 13, 2025공시 • Apr 08CellSeed Inc. to Report Q1, 2025 Results on May 13, 2025CellSeed Inc. announced that they will report Q1, 2025 results on May 13, 2025New Risk • Mar 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (9.7% average weekly change).공시 • Feb 13CellSeed Inc., Annual General Meeting, Mar 25, 2025CellSeed Inc., Annual General Meeting, Mar 25, 2025.New Risk • Dec 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.3b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (JP¥15.3b market cap, or US$99.7m).공시 • Dec 03CellSeed Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025CellSeed Inc. announced that they will report fiscal year 2024 results on Feb 13, 2025공시 • Oct 21CellSeed Inc. to Report Nine Months, 2024 Results on Nov 14, 2024CellSeed Inc. announced that they will report nine months, 2024 results on Nov 14, 2024공시 • Jun 22CellSeed Inc. to Report Q2, 2024 Results on Aug 13, 2024CellSeed Inc. announced that they will report Q2, 2024 results on Aug 13, 2024New Risk • May 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (JP¥8.82b market cap, or US$56.3m).공시 • Apr 26CellSeed Inc. to Report Q1, 2024 Results on May 13, 2024CellSeed Inc. announced that they will report Q1, 2024 results on May 13, 2024공시 • Feb 13CellSeed Inc., Annual General Meeting, Mar 26, 2024CellSeed Inc., Annual General Meeting, Mar 26, 2024.공시 • Feb 08MetaTech (AP) Inc. Files Lawsuit Against CellSeed IncMetaTech (AP) Inc. has filed a lawsuit in Japan to confirm the existence of the contractual relationship between CellSeed Inc. about Collaboration Agreement etc. Details of occurrence (including the matter under dispute): CellSeed law firm commissioned the Baker McKenzie to send a lawyer's letter on 2023/12/19. In the absence of specific evidence and solely relying on media reports, they unilaterally claimed that company breached the Collaboration Agreement and terminated various contracts signed by both parties. To protect own interests, company has engaged Japanese lawyers to file a lawsuit in the Tokyo District Court in Japan to confirm the existence of the contractual relationship.공시 • Jan 13CellSeed Inc. to Report Fiscal Year 2023 Results on Feb 13, 2024CellSeed Inc. announced that they will report fiscal year 2023 results on Feb 13, 2024공시 • Oct 24CellSeed Inc. to Report Nine Months, 2023 Results on Nov 14, 2023CellSeed Inc. announced that they will report nine months, 2023 results on Nov 14, 2023공시 • Jul 24CellSeed Inc. to Report First Half, 2023 Results on Aug 14, 2023CellSeed Inc. announced that they will report first half, 2023 results on Aug 14, 2023공시 • Jun 06CellSeed Inc. announced that it has received ¥2.001 million in funding from Barclays Bank PLC, Investment ArmOn June 5, 2023, CellSeed Inc. closed the transaction.공시 • May 17MetaTech (AP) Inc.,CHUN-LUNGWU and AlexCHEN agreed to acquire 12.69% stake in Up Cell Biomedical Co. from CellSeed Inc. (TSE:7776).MetaTech (AP) Inc.,CHUN-LUNGWU and AlexCHEN agreed to acquire 12.69% stake in Up Cell Biomedical Co. from CellSeed Inc. (TSE:7776) on May 15, 2023. Transfer execution date is June to late July 2023.공시 • May 16CellSeed Inc. announced that it expects to receive ¥2.001 million in funding from Barclays Bank PLC, Investment ArmCellSeed Inc. announced a private placement of of 69,000 24th stock acquisition rights at ¥29 per warrant for gross proceeds of ¥2,001,000 on May 15, 2023. The transaction will involve participation from returning investor Barclays Bank PLC, Investment Arm. The warrants will be exercisable into 6,900,000 common shares of the company. The minimum exercise price of warrants is ¥178 per share. The warrants will be exercisable from allocation date to June 12, 2025. The company will issue securities through third-party allotment. The transaction has been approved by the board of directors of the company. The transaction is expected to close between June 5, 2023 and June 12, 2023.Board Change • Apr 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Outside Director Toshio Yamaguchi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Feb 15CellSeed Inc., Annual General Meeting, Mar 28, 2023CellSeed Inc., Annual General Meeting, Mar 28, 2023.공시 • Jan 24CellSeed Inc. to Report Fiscal Year 2022 Results on Feb 14, 2023CellSeed Inc. announced that they will report fiscal year 2022 results on Feb 14, 2023공시 • Oct 27CellSeed Inc. to Report Nine Months, 2022 Results on Nov 14, 2022CellSeed Inc. announced that they will report nine months, 2022 results on Nov 14, 2022공시 • May 03CellSeed Inc. to Report Q1, 2022 Results on May 12, 2022CellSeed Inc. announced that they will report Q1, 2022 results on May 12, 2022Reported Earnings • Apr 02Full year 2021 earnings released: JP¥53.14 loss per share (vs JP¥55.25 loss in FY 2020)Full year 2021 results: JP¥53.14 loss per share. Revenue: JP¥161.0m (down 19% from FY 2020). Net loss: JP¥914.0m (loss widened 17% from FY 2020).Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥53.14 loss per share (up from JP¥55.25 loss in FY 2020). Revenue: JP¥161.0m (down 19% from FY 2020). Net loss: JP¥914.0m (loss widened 17% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 45% per year whereas the company’s share price has fallen by 41% per year.공시 • Feb 15CellSeed Inc., Annual General Meeting, Mar 25, 2022CellSeed Inc., Annual General Meeting, Mar 25, 2022.공시 • Jan 06CellSeed Inc. announced that it has received ¥1.144 million in funding from Barclays Bank PLC, Investment ArmOn January 5, 2022, CellSeed Inc. closed the transaction.공시 • Dec 21CellSeed Inc. announced that it expects to receive ¥1.144 million in funding from Barclays Bank PLC, Investment ArmCellSeed Inc. announced a private placement of 44,000 22nd stock acquisition rights at ¥26 per warrant for gross proceeds of ¥1,144,000 on December 20, 2021. The transaction will involve participation from Barclays Bank PLC, Investment Arm. The allotment date for warrants is January 5, 2022. The warrants will be exercisable into 4,400,000 common shares of the company at an initial exercise price of ¥196 per share, revisable. The minimum exercise price of warrants is ¥98 per share. The warrants will be exercisable From January 6, 2022 to January 5, 2023. The company will issue securities through third-party allotment. The transaction has been approved by board of directors of the company.Reported Earnings • Nov 13Third quarter 2021 earnings released: JP¥12.24 loss per share (vs JP¥18.78 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥47.0m (up 88% from 3Q 2020). Net loss: JP¥217.0m (loss narrowed 20% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 18Second quarter 2021 earnings released: JP¥14.17 loss per share (vs JP¥11.41 loss in 2Q 2020)The company reported a mediocre second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: JP¥40.0m (up 48% from 2Q 2020). Net loss: JP¥240.0m (loss widened 52% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year and the company’s share price has also fallen by 37% per year.Reported Earnings • May 16First quarter 2021 earnings released: JP¥15.04 loss per share (vs JP¥13.69 loss in 1Q 2020)The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: JP¥41.0m (up 32% from 1Q 2020). Net loss: JP¥246.0m (loss widened 35% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Feb 18New 90-day high: JP¥290The company is up 3.0% from its price of JP¥281 on 20 November 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.공시 • Feb 16CellSeed Inc., Annual General Meeting, Mar 26, 2021CellSeed Inc., Annual General Meeting, Mar 26, 2021.Reported Earnings • Feb 14Full year 2020 earnings released: JP¥55.25 loss per share (vs JP¥66.57 loss in FY 2019)The company reported a poor full year result with weaker revenues, weaker control over costs and no improvement to losses. Full year 2020 results: Revenue: JP¥199.0m (down 28% from FY 2019). Net loss: JP¥783.0m (flat on FY 2019). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Dec 28New 90-day low: JP¥225The company is down 35% from its price of JP¥348 on 29 September 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.Is New 90 Day High Low • Dec 09New 90-day low: JP¥264The company is down 22% from its price of JP¥339 on 10 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.분석 기사 • Nov 17Is CellSeed (TYO:7776) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Nov 15Third quarter 2020 earnings released: JP¥18.78 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: JP¥25.0m (down 48% from 3Q 2019). Net loss: JP¥271.0m (loss widened 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 11New 90-day low: JP¥295The company is down 16% from its price of JP¥350 on 13 August 2020. The Japanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.공시 • Nov 10CellSeed Inc. to Report Fiscal Year 2020 Results on Feb 14, 2021CellSeed Inc. announced that they will report fiscal year 2020 results at 12:30 PM, GMT Standard Time on Feb 14, 2021Is New 90 Day High Low • Oct 15New 90-day low: JP¥319The company is down 14% from its price of JP¥372 on 17 July 2020. The Japanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 12% over the same period.공시 • Aug 07+ 1 more updateCellSeed Inc. announced that it has received ¥3.78 million in funding from Barclays Bank PLC, Investment ArmOn August 6, 2020, CellSeed Inc. (JASDAQ:7776) closed the transaction.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 7776 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 7776 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장CellSeed 배당 수익률 vs 시장7776의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (7776)n/a시장 하위 25% (JP)1.7%시장 상위 25% (JP)3.8%업계 평균 (Biotechs)1.3%분석가 예측 (7776) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 7776 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 7776 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 7776 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 7776 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YJP 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/29 11:18종가2026/05/29 00:00수익2021/12/31연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스CellSeed Inc.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kiyokazu YamazakiIchiyoshi Research Institute Inc.null nullInvestment Bridge Co., Ltd.Kyoichiro ShigemuraNomura Securities Co. Ltd.
공시 • Apr 24CellSeed Inc. to Report Q1, 2026 Results on May 13, 2026CellSeed Inc. announced that they will report Q1, 2026 results on May 13, 2026
공시 • Feb 16CellSeed Inc., Annual General Meeting, Mar 25, 2026CellSeed Inc., Annual General Meeting, Mar 25, 2026.
공시 • Dec 03CellSeed Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026CellSeed Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026
공시 • Nov 20CellSeed Inc. announced that it expects to receive ¥3.44 million in funding from Barclays Bank PLC, Investment ArmCellSeed Inc. announced a private placement by the Resolution of the Board of Directors to issue 86,000 25th Series of Stock Acquisition Rights at a price of ¥40 per stock acquisition right for gross proceeds of ¥3,440,000 on November 20, 2025. The transaction includes participation from Barclays Bank PLC. The Stock Acquisition Rights are convertible into 8,600,000 Ordinary Shares for gross proceeds of ¥3,268,000,000. The initial exercise price will be ¥380. On or after December 9, 2025, the exercise price will be revised on the effective date of each exercise request for the Stock Acquisition Rights to an amount equivalent to 97% of the closing price of the Company's common shares in regular trading on the Tokyo Stock Exchange on the trading day immediately preceding the revision date. If the revised exercise price based on this calculation falls below the minimum exercise price, the minimum exercise price will be the revised exercise price. The exercise period starts from from December 9, 2025 to December 8, 2027.
New Risk • Oct 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).
New Risk • Oct 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.5b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Market cap is less than US$100m (JP¥14.5b market cap, or US$99.1m).
공시 • Sep 27CellSeed Inc. to Report Q3, 2025 Results on Nov 13, 2025CellSeed Inc. announced that they will report Q3, 2025 results on Nov 13, 2025
공시 • Jun 17CellSeed Inc. to Report Q2, 2025 Results on Aug 13, 2025CellSeed Inc. announced that they will report Q2, 2025 results on Aug 13, 2025
공시 • Apr 08CellSeed Inc. to Report Q1, 2025 Results on May 13, 2025CellSeed Inc. announced that they will report Q1, 2025 results on May 13, 2025
New Risk • Mar 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (9.7% average weekly change).
공시 • Feb 13CellSeed Inc., Annual General Meeting, Mar 25, 2025CellSeed Inc., Annual General Meeting, Mar 25, 2025.
New Risk • Dec 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥15.3b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (JP¥15.3b market cap, or US$99.7m).
공시 • Dec 03CellSeed Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025CellSeed Inc. announced that they will report fiscal year 2024 results on Feb 13, 2025
공시 • Oct 21CellSeed Inc. to Report Nine Months, 2024 Results on Nov 14, 2024CellSeed Inc. announced that they will report nine months, 2024 results on Nov 14, 2024
공시 • Jun 22CellSeed Inc. to Report Q2, 2024 Results on Aug 13, 2024CellSeed Inc. announced that they will report Q2, 2024 results on Aug 13, 2024
New Risk • May 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (JP¥8.82b market cap, or US$56.3m).
공시 • Apr 26CellSeed Inc. to Report Q1, 2024 Results on May 13, 2024CellSeed Inc. announced that they will report Q1, 2024 results on May 13, 2024
공시 • Feb 13CellSeed Inc., Annual General Meeting, Mar 26, 2024CellSeed Inc., Annual General Meeting, Mar 26, 2024.
공시 • Feb 08MetaTech (AP) Inc. Files Lawsuit Against CellSeed IncMetaTech (AP) Inc. has filed a lawsuit in Japan to confirm the existence of the contractual relationship between CellSeed Inc. about Collaboration Agreement etc. Details of occurrence (including the matter under dispute): CellSeed law firm commissioned the Baker McKenzie to send a lawyer's letter on 2023/12/19. In the absence of specific evidence and solely relying on media reports, they unilaterally claimed that company breached the Collaboration Agreement and terminated various contracts signed by both parties. To protect own interests, company has engaged Japanese lawyers to file a lawsuit in the Tokyo District Court in Japan to confirm the existence of the contractual relationship.
공시 • Jan 13CellSeed Inc. to Report Fiscal Year 2023 Results on Feb 13, 2024CellSeed Inc. announced that they will report fiscal year 2023 results on Feb 13, 2024
공시 • Oct 24CellSeed Inc. to Report Nine Months, 2023 Results on Nov 14, 2023CellSeed Inc. announced that they will report nine months, 2023 results on Nov 14, 2023
공시 • Jul 24CellSeed Inc. to Report First Half, 2023 Results on Aug 14, 2023CellSeed Inc. announced that they will report first half, 2023 results on Aug 14, 2023
공시 • Jun 06CellSeed Inc. announced that it has received ¥2.001 million in funding from Barclays Bank PLC, Investment ArmOn June 5, 2023, CellSeed Inc. closed the transaction.
공시 • May 17MetaTech (AP) Inc.,CHUN-LUNGWU and AlexCHEN agreed to acquire 12.69% stake in Up Cell Biomedical Co. from CellSeed Inc. (TSE:7776).MetaTech (AP) Inc.,CHUN-LUNGWU and AlexCHEN agreed to acquire 12.69% stake in Up Cell Biomedical Co. from CellSeed Inc. (TSE:7776) on May 15, 2023. Transfer execution date is June to late July 2023.
공시 • May 16CellSeed Inc. announced that it expects to receive ¥2.001 million in funding from Barclays Bank PLC, Investment ArmCellSeed Inc. announced a private placement of of 69,000 24th stock acquisition rights at ¥29 per warrant for gross proceeds of ¥2,001,000 on May 15, 2023. The transaction will involve participation from returning investor Barclays Bank PLC, Investment Arm. The warrants will be exercisable into 6,900,000 common shares of the company. The minimum exercise price of warrants is ¥178 per share. The warrants will be exercisable from allocation date to June 12, 2025. The company will issue securities through third-party allotment. The transaction has been approved by the board of directors of the company. The transaction is expected to close between June 5, 2023 and June 12, 2023.
Board Change • Apr 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Outside Director Toshio Yamaguchi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Feb 15CellSeed Inc., Annual General Meeting, Mar 28, 2023CellSeed Inc., Annual General Meeting, Mar 28, 2023.
공시 • Jan 24CellSeed Inc. to Report Fiscal Year 2022 Results on Feb 14, 2023CellSeed Inc. announced that they will report fiscal year 2022 results on Feb 14, 2023
공시 • Oct 27CellSeed Inc. to Report Nine Months, 2022 Results on Nov 14, 2022CellSeed Inc. announced that they will report nine months, 2022 results on Nov 14, 2022
공시 • May 03CellSeed Inc. to Report Q1, 2022 Results on May 12, 2022CellSeed Inc. announced that they will report Q1, 2022 results on May 12, 2022
Reported Earnings • Apr 02Full year 2021 earnings released: JP¥53.14 loss per share (vs JP¥55.25 loss in FY 2020)Full year 2021 results: JP¥53.14 loss per share. Revenue: JP¥161.0m (down 19% from FY 2020). Net loss: JP¥914.0m (loss widened 17% from FY 2020).
Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥53.14 loss per share (up from JP¥55.25 loss in FY 2020). Revenue: JP¥161.0m (down 19% from FY 2020). Net loss: JP¥914.0m (loss widened 17% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 45% per year whereas the company’s share price has fallen by 41% per year.
공시 • Feb 15CellSeed Inc., Annual General Meeting, Mar 25, 2022CellSeed Inc., Annual General Meeting, Mar 25, 2022.
공시 • Jan 06CellSeed Inc. announced that it has received ¥1.144 million in funding from Barclays Bank PLC, Investment ArmOn January 5, 2022, CellSeed Inc. closed the transaction.
공시 • Dec 21CellSeed Inc. announced that it expects to receive ¥1.144 million in funding from Barclays Bank PLC, Investment ArmCellSeed Inc. announced a private placement of 44,000 22nd stock acquisition rights at ¥26 per warrant for gross proceeds of ¥1,144,000 on December 20, 2021. The transaction will involve participation from Barclays Bank PLC, Investment Arm. The allotment date for warrants is January 5, 2022. The warrants will be exercisable into 4,400,000 common shares of the company at an initial exercise price of ¥196 per share, revisable. The minimum exercise price of warrants is ¥98 per share. The warrants will be exercisable From January 6, 2022 to January 5, 2023. The company will issue securities through third-party allotment. The transaction has been approved by board of directors of the company.
Reported Earnings • Nov 13Third quarter 2021 earnings released: JP¥12.24 loss per share (vs JP¥18.78 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥47.0m (up 88% from 3Q 2020). Net loss: JP¥217.0m (loss narrowed 20% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 18Second quarter 2021 earnings released: JP¥14.17 loss per share (vs JP¥11.41 loss in 2Q 2020)The company reported a mediocre second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: JP¥40.0m (up 48% from 2Q 2020). Net loss: JP¥240.0m (loss widened 52% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year and the company’s share price has also fallen by 37% per year.
Reported Earnings • May 16First quarter 2021 earnings released: JP¥15.04 loss per share (vs JP¥13.69 loss in 1Q 2020)The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: JP¥41.0m (up 32% from 1Q 2020). Net loss: JP¥246.0m (loss widened 35% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Feb 18New 90-day high: JP¥290The company is up 3.0% from its price of JP¥281 on 20 November 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.
공시 • Feb 16CellSeed Inc., Annual General Meeting, Mar 26, 2021CellSeed Inc., Annual General Meeting, Mar 26, 2021.
Reported Earnings • Feb 14Full year 2020 earnings released: JP¥55.25 loss per share (vs JP¥66.57 loss in FY 2019)The company reported a poor full year result with weaker revenues, weaker control over costs and no improvement to losses. Full year 2020 results: Revenue: JP¥199.0m (down 28% from FY 2019). Net loss: JP¥783.0m (flat on FY 2019). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Dec 28New 90-day low: JP¥225The company is down 35% from its price of JP¥348 on 29 September 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.
Is New 90 Day High Low • Dec 09New 90-day low: JP¥264The company is down 22% from its price of JP¥339 on 10 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period.
분석 기사 • Nov 17Is CellSeed (TYO:7776) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Nov 15Third quarter 2020 earnings released: JP¥18.78 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: JP¥25.0m (down 48% from 3Q 2019). Net loss: JP¥271.0m (loss widened 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 11New 90-day low: JP¥295The company is down 16% from its price of JP¥350 on 13 August 2020. The Japanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.
공시 • Nov 10CellSeed Inc. to Report Fiscal Year 2020 Results on Feb 14, 2021CellSeed Inc. announced that they will report fiscal year 2020 results at 12:30 PM, GMT Standard Time on Feb 14, 2021
Is New 90 Day High Low • Oct 15New 90-day low: JP¥319The company is down 14% from its price of JP¥372 on 17 July 2020. The Japanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 12% over the same period.
공시 • Aug 07+ 1 more updateCellSeed Inc. announced that it has received ¥3.78 million in funding from Barclays Bank PLC, Investment ArmOn August 6, 2020, CellSeed Inc. (JASDAQ:7776) closed the transaction.